ANTI-POLLUTION 67 Lipid damage study


Malondialdehyde content determination was used as oxidative stress index linked to the lipid component. To determine the lipoperoxides levels the colorimetric method tested by Erdelmeier and collaborators (1998) was assayed: the test is based on the capability of a chromogen, N methyl 2 phenylindole (NMPI), to react with MDA at 45°C with acid pH to produce a stable blue chromophore that has an absorption pick at 586 nm. The quantitative determination uses a calibration curve made-up of known and growing concentrations of standard MDA. The results are expressed as MDA concentration (μM) in 100 μL cell homogenate. Three trials were performed for each


determination. Results are shown in Fig 3. In vitro tests on the natural active shield capacity of protecting tissues from urban dust on all parameters studied (cell viability, metabolism and lipoeproxidation) always show positive effects linked to the use of the active ingredient, forecasting its potential effect on humans as a strong anti- pollution agent.


Blue light protection The in vitro evaluation of the high-energy visible (HEV -400-500 nm) light absorbance and protection activity demonstrated that,


7 +26% 6 5 4 3 2 1 0 Lipoperoxidation  CTR–  CTR+  Plerasan Veil500 Figure 3: Lipid damage study.


at 1%, the natural active shield determined an increase of the absorbance in the HEV (400-500 nm) spectrum, and therefore it can block part of the irradiated light coming from screens and mobile phones.


Specific control of proved efficacy In vivo results are guaranteed by a


correlation to a specific in vitro “efficacy control” test, performed at every batch of the ingredient. In fact, to be validated for the market sales, every production of the natural active shield has to demonstrate its compliance for an efficacy parameter: the protective effect against chemical agent (keratinocytes, 24h, 1%), reaching a


February 2020


PERSONAL CARE EUROPE


MDA content (µM)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92